Novo Nordisk ZEUS Trial Misses Heart Endpoint
Novo Nordisk ZEUS trial failed to reduce MACE, prompting a planned non-cash impairment and likely pressuring trading flows while guidance stays intact.
KEY TAKEAWAYS
- ZEUS failed to significantly reduce MACE in a trial of more than 6,300 patients.
- Result will produce a non-cash impairment charge in Q3 while leaving 2026 adjusted operating profit outlook intact.
- Two other ziltivekimab trials remain on track with readouts expected in 1H 2027.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk (NVO) said in an official update on July 31, 2026, that its ZEUS trial of ziltivekimab did not significantly reduce major adverse cardiovascular events (MACE), a composite of death, non-fatal heart attack, and non-fatal stroke. The clinical setback will prompt a planned non-cash impairment but will not affect the company’s adjusted operating-profit outlook for 2026.
ZEUS Trial Results and Safety Profile
The Phase 3 ZEUS trial enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation. The study failed to meet a minimum 15% relative-risk-reduction threshold that analysts had identified as important for the drug’s commercial and regulatory prospects.
The update said overall side effects and serious adverse events were similar between the ziltivekimab and placebo groups, although serious infections occurred more frequently in patients receiving the drug.
Financial Impact and Pipeline Outlook
Novo Nordisk said the ZEUS outcome will trigger a non-cash impairment charge in the third quarter but will not change its 2026 adjusted operating-profit guidance. Two other ziltivekimab trials—in heart failure patients and those recovering from acute heart attacks—are ongoing, with results expected in the first half of 2027.
The trial’s failure to demonstrate a significant MACE benefit may weaken the candidate’s future commercial and regulatory potential.
